Emergent BioSolutions, filed three complaints to the Securities and Exchange Commission June 6, including the allegation that J&J didn’t deliver “forecasts of the required quantity of product to be purchased” and didn’t meet minimum requirements in the two-year agreement.
Emergent said a terminated contract will cost J&J $125 million to $420 million.
In response, J&J handed Emergent a “formal notice of termination” and said the filing “is false and misleading” the same day, according to the Wall Street Journal. J&J said Emergent failed “to supply the COVID-19 vaccine drug substance” after ingredients for about 400 million doses were contaminated in May.
Read the full story here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
